Researchers have found that aromatase inhibitors like anastrozole are more effective in treating postmenopausal women with hormone receptor-positive early breast cancer than tamoxifen according to study published in the "The Lancet Oncology" journal.
Researchers followed more than 6,000 postmenopausal women with early breast cancer for more than 5 years and found that patients on anastrozole had much less adverse effects and the drug was well tolerated by patients.
Majority of adverse effects with tamoxifen occurred during the first 2.5 years of treatment leading to patients withdrawing from treatment, but this was much less in patients on anastrozole. The drug also had a significantly better risk-benefit profile one to two years after treatment when compared to tamoxifen.
This has led to the conclusion that aromatase inhibitors are more effective for initial treatment after surgery than tamoxifen for treating postmenopausal women with early hormone receptor-sensitive breast cancer.